Trilostane Dose versus Body Weight in the Treatment of Naturally Occurring Pituitary-Dependent Hyperadrenocorticism in Dogs

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature. Hypothesis: As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Animals: 70 dogs with naturally occurring hyperadrenocorticism. Methods: Retrospective study. Each dog must have been treated for at least 6 months and should have shown a "good response" to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition. Results: There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases. Conclusions and Clinical Importance: Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.

Original languageEnglish (US)
Pages (from-to)1078-1080
Number of pages3
JournalJournal of Veterinary Internal Medicine
Volume26
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

Adrenocortical Hyperfunction
hyperadrenocorticism
Body Weight
Dogs
body weight
dogs
dosage
trilostane
Body Surface Area
Retrospective Studies
Regression Analysis
retrospective studies
surface area
regression analysis

Keywords

  • Hyperadrenocorticism
  • Pituitary-dependent hyperadrenocorticism
  • Trilostane

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{5bd74ede2f4f4f1a9d6b74fd043cba89,
title = "Trilostane Dose versus Body Weight in the Treatment of Naturally Occurring Pituitary-Dependent Hyperadrenocorticism in Dogs",
abstract = "Background: Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature. Hypothesis: As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Animals: 70 dogs with naturally occurring hyperadrenocorticism. Methods: Retrospective study. Each dog must have been treated for at least 6 months and should have shown a {"}good response{"} to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition. Results: There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases. Conclusions and Clinical Importance: Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.",
keywords = "Hyperadrenocorticism, Pituitary-dependent hyperadrenocorticism, Trilostane",
author = "Feldman, {Edward C} and Kass, {Philip H}",
year = "2012",
month = "7",
doi = "10.1111/j.1939-1676.2012.00956.x",
language = "English (US)",
volume = "26",
pages = "1078--1080",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Trilostane Dose versus Body Weight in the Treatment of Naturally Occurring Pituitary-Dependent Hyperadrenocorticism in Dogs

AU - Feldman, Edward C

AU - Kass, Philip H

PY - 2012/7

Y1 - 2012/7

N2 - Background: Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature. Hypothesis: As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Animals: 70 dogs with naturally occurring hyperadrenocorticism. Methods: Retrospective study. Each dog must have been treated for at least 6 months and should have shown a "good response" to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition. Results: There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases. Conclusions and Clinical Importance: Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.

AB - Background: Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature. Hypothesis: As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases. Animals: 70 dogs with naturally occurring hyperadrenocorticism. Methods: Retrospective study. Each dog must have been treated for at least 6 months and should have shown a "good response" to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1-20, 20.1-30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition. Results: There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases. Conclusions and Clinical Importance: Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.

KW - Hyperadrenocorticism

KW - Pituitary-dependent hyperadrenocorticism

KW - Trilostane

UR - http://www.scopus.com/inward/record.url?scp=84864020602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864020602&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2012.00956.x

DO - 10.1111/j.1939-1676.2012.00956.x

M3 - Article

VL - 26

SP - 1078

EP - 1080

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 4

ER -